ProfileGDS4814 / ILMN_1759023
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 90% 89% 87% 91% 89% 88% 87% 91% 89% 87% 91% 90% 88% 90% 90% 90% 90% 90% 91% 90% 90% 91% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)434.20290
GSM780708Untreated after 4 days (C2_1)341.98889
GSM780709Untreated after 4 days (C3_1)283.50687
GSM780719Untreated after 4 days (C1_2)497.18191
GSM780720Untreated after 4 days (C2_2)379.59589
GSM780721Untreated after 4 days (C3_2)323.45788
GSM780710Trastuzumab treated after 4 days (T1_1)277.31387
GSM780711Trastuzumab treated after 4 days (T2_1)455.74391
GSM780712Trastuzumab treated after 4 days (T3_1)355.12189
GSM780722Trastuzumab treated after 4 days (T1_2)272.77187
GSM780723Trastuzumab treated after 4 days (T2_2)443.42991
GSM780724Trastuzumab treated after 4 days (T3_2)387.29190
GSM780713Pertuzumab treated after 4 days (P1_1)331.3288
GSM780714Pertuzumab treated after 4 days (P2_1)391.7690
GSM780715Pertuzumab treated after 4 days (P3_1)424.83890
GSM780725Pertuzumab treated after 4 days (P1_2)401.3490
GSM780726Pertuzumab treated after 4 days (P2_2)384.6890
GSM780727Pertuzumab treated after 4 days (P3_2)409.91390
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)474.34691
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)418.50890
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)416.84290
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)462.87591
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)407.87590